ProPhase Labs Divests PMI, Diagnostics Unit Files for Bankruptcy
ProPhase Labs, Inc. has undergone significant operational changes, with its ProPhase Diagnostics subsidiary filing for Chapter 11 bankruptcy on September 22, 2025, due to a sharp decline in COVID-19 testing demand and reimbursement. Concurrently, the company divested its Pharmaloz Contract Manufacturing (PMI) unit on January 16, 2025, which included a $2 million cash payment and the extinguishment of approximately $11 million in debt. The company continues to focus on its growth-oriented biotech, genomics, and consumer products segments, including the development of the BE-Smart Esophageal Pre-Cancer diagnostic test and the Linebacker (LB-1 and LB-2) cancer therapies, alongside its Nebula Genomics, DNA Complete, and TK Supplements offerings.
Key Highlights
- ProPhase Diagnostics filed for Chapter 11 bankruptcy on September 22, 2025, due to decreased COVID-19 testing demand and reimbursement rates.
- ProPhase Labs deconsolidated ProPhase Diagnostics as of September 22, 2025.
- Sold Pharmaloz Contract Manufacturing (PMI) on January 16, 2025, receiving $2 million cash and extinguishing approximately $11 million in debt.
- Continuing development of BE-Smart Esophageal Pre-Cancer diagnostic test, with initial data showing potential for early detection.
- Preclinical studies for Linebacker LB-1 showed significant inhibition of cell proliferation when combined with chemotherapy drugs, up to 97.18% with Topotecan.
- Ongoing collaboration with Dana-Farber Cancer Institute and Harvard Medical School for LB-1 research.
- Offers whole genome sequencing and related services through Nebula Genomics and DNA Complete.
- Markets dietary supplements under the TK Supplements® brand, including Legendz XL® and Triple Edge XL®.
Price Impact